Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current PTGX market cap is 2.61B. The company's latest EPS is USD -1.3248 and P/E is -33.06.
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 0 | 0 | 60M | 254.95M | 4.17M |
| Operating Income | -42.35M | -38.33M | 23.05M | 206.31M | -38.79M |
| Net Income | -38.46M | -34.11M | 27.34M | 207.34M | -30.62M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 231k | 28.63M | 27.36M | 26.58M | 60M |
| Operating Income | -80.52M | -64.52M | -125.85M | -131.37M | -93.65M |
| Net Income | -77.19M | -66.15M | -125.55M | -127.39M | -78.96M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 320.47M | 330.02M | 357.95M | 629.28M | 614.63M |
| Total Liabilities | 26.4M | 27.87M | 21.27M | 68.83M | 73.31M |
| Total Equity | 294.07M | 302.15M | 336.68M | 560.44M | 541.32M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 154.92M | 324.47M | 347.7M | 247.93M | 357.95M |
| Total Liabilities | 74.95M | 44.86M | 47.67M | 32.32M | 21.27M |
| Total Equity | 79.96M | 279.61M | 300.02M | 215.61M | 336.68M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -60.59M | -87.2M | -70.24M | -27.43M | 241.19M |
| Investing | 35.59M | 22.03M | -39.26M | 6.07M | -82.05M |
| Financing | 134.64M | 169.95M | 170.48M | 7.2M | 10.37M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -41.53M | -72.48M | -107.87M | -108.14M | -70.24M |
| Investing | -53.71M | -90.97M | -15.86M | 91.47M | -39.26M |
| Financing | 46.04M | 247.63M | 129.92M | 18.84M | 170.48M |
| Market Cap | 2.61B |
| Price to Earnings Ratio | -33.06 |
| Price to Sales Ratio | 43.51 |
| Price to Cash Ratio | 13.98 |
| Price to Book Ratio | 7.75 |
| Dividend Yield | - |
| Shares Outstanding | 59.6M |
| Average Volume (1 week) | 965.88k |
| Average Volume (1 Month) | 878.86k |
| 52 Week Change | 148.44% |
| 52 Week High | 48.89 |
| 52 Week Low | 17.57 |
| Spread (Intraday) | 7.75 (15.9%) |
| Company Name | Protagonist Therapeutics Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.protagonist-inc.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
